Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2021-01, Vol.329, p.758-761 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 761 |
|---|---|
| container_issue | |
| container_start_page | 758 |
| container_title | Journal of controlled release |
| container_volume | 329 |
| creator | Formiga, Fabio Rocha Leblanc, Roger de Souza Rebouças, Juliana Farias, Leonardo Paiva de Oliveira, Ronaldo Nascimento Pena, Lindomar |
| description | Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
[Display omitted]
•Ivermectin is an FDA-approved antiparasitic agent, being currently investigated in COVID-19 patients•Ivermectin for COVID-19 is restrained by formulation challenges, whereas only oral dosage forms are available•The delivery of ivermectin by pulmonary route would provide high drug deposition in the airways and lungs•Expected efficacy by using aerosol micro- and nanocarriers containing ivermectin |
| doi_str_mv | 10.1016/j.jconrel.2020.10.009 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7539925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365920305800</els_id><sourcerecordid>S0168365920305800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-3b111023eeb0d7124ca6830cbcefeed044e18ca7f500c100770705c27ab718693</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EouXxCaD8QMo4TuKYBQiVV6VKXfDYWo4zSV21TuWkLf17HLVUsGJla-beOzOHkCsKAwo0vZkNZrq2DueDCKKuNgAQR6RPM87CWIjkmPS9LgtZmogeOWuaGQAkLOanpMcYsCyORZ-8jdboFqhbY28DZQO1Ua4IN8ZaY6ugcKsq2Jh2GuDX0ouw8JrWrI1T80Dp7tduA1UpY5s2GE4-R48hFRfkpFTzBi_37zn5eH56H76G48nLaPgwDnWc8jZkOaUUIoaYQ8FpFGuVZgx0rrFELCCOkWZa8TIB0BSAc-CQ6IirnNMsFeyc3O1yl6t8gYVG2_q95NKZhXJbWSsj_3asmcqqXkueMCGixAckuwDt6qZxWB68FGRHWc7knrLsKHdlT9n7rn8PPrh-sHrB_U6A_vy1QScbbdBqLIzzGGVRm39GfAP0lJIy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ivermectin: an award-winning drug with expected antiviral activity against COVID-19</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Formiga, Fabio Rocha ; Leblanc, Roger ; de Souza Rebouças, Juliana ; Farias, Leonardo Paiva ; de Oliveira, Ronaldo Nascimento ; Pena, Lindomar</creator><creatorcontrib>Formiga, Fabio Rocha ; Leblanc, Roger ; de Souza Rebouças, Juliana ; Farias, Leonardo Paiva ; de Oliveira, Ronaldo Nascimento ; Pena, Lindomar</creatorcontrib><description>Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
[Display omitted]
•Ivermectin is an FDA-approved antiparasitic agent, being currently investigated in COVID-19 patients•Ivermectin for COVID-19 is restrained by formulation challenges, whereas only oral dosage forms are available•The delivery of ivermectin by pulmonary route would provide high drug deposition in the airways and lungs•Expected efficacy by using aerosol micro- and nanocarriers containing ivermectin</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2020.10.009</identifier><identifier>PMID: 33038449</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Inhalation ; Administration, Oral ; Aerosols ; Antiviral Agents - administration & dosage ; Antiviral Agents - therapeutic use ; COVID-19 - drug therapy ; Drug Carriers - chemistry ; Drug Compounding ; Drug Therapy, Combination ; Humans ; Ivermectin - administration & dosage ; Ivermectin - therapeutic use ; Nanoparticles - chemistry ; Randomized Controlled Trials as Topic ; SARS-CoV-2 - drug effects ; Treatment Outcome</subject><ispartof>Journal of controlled release, 2021-01, Vol.329, p.758-761</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-3b111023eeb0d7124ca6830cbcefeed044e18ca7f500c100770705c27ab718693</citedby><cites>FETCH-LOGICAL-c467t-3b111023eeb0d7124ca6830cbcefeed044e18ca7f500c100770705c27ab718693</cites><orcidid>0000-0003-1553-0533</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2020.10.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33038449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Formiga, Fabio Rocha</creatorcontrib><creatorcontrib>Leblanc, Roger</creatorcontrib><creatorcontrib>de Souza Rebouças, Juliana</creatorcontrib><creatorcontrib>Farias, Leonardo Paiva</creatorcontrib><creatorcontrib>de Oliveira, Ronaldo Nascimento</creatorcontrib><creatorcontrib>Pena, Lindomar</creatorcontrib><title>Ivermectin: an award-winning drug with expected antiviral activity against COVID-19</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
[Display omitted]
•Ivermectin is an FDA-approved antiparasitic agent, being currently investigated in COVID-19 patients•Ivermectin for COVID-19 is restrained by formulation challenges, whereas only oral dosage forms are available•The delivery of ivermectin by pulmonary route would provide high drug deposition in the airways and lungs•Expected efficacy by using aerosol micro- and nanocarriers containing ivermectin</description><subject>Administration, Inhalation</subject><subject>Administration, Oral</subject><subject>Aerosols</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>COVID-19 - drug therapy</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Compounding</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Ivermectin - administration & dosage</subject><subject>Ivermectin - therapeutic use</subject><subject>Nanoparticles - chemistry</subject><subject>Randomized Controlled Trials as Topic</subject><subject>SARS-CoV-2 - drug effects</subject><subject>Treatment Outcome</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EouXxCaD8QMo4TuKYBQiVV6VKXfDYWo4zSV21TuWkLf17HLVUsGJla-beOzOHkCsKAwo0vZkNZrq2DueDCKKuNgAQR6RPM87CWIjkmPS9LgtZmogeOWuaGQAkLOanpMcYsCyORZ-8jdboFqhbY28DZQO1Ua4IN8ZaY6ugcKsq2Jh2GuDX0ouw8JrWrI1T80Dp7tduA1UpY5s2GE4-R48hFRfkpFTzBi_37zn5eH56H76G48nLaPgwDnWc8jZkOaUUIoaYQ8FpFGuVZgx0rrFELCCOkWZa8TIB0BSAc-CQ6IirnNMsFeyc3O1yl6t8gYVG2_q95NKZhXJbWSsj_3asmcqqXkueMCGixAckuwDt6qZxWB68FGRHWc7knrLsKHdlT9n7rn8PPrh-sHrB_U6A_vy1QScbbdBqLIzzGGVRm39GfAP0lJIy</recordid><startdate>20210110</startdate><enddate>20210110</enddate><creator>Formiga, Fabio Rocha</creator><creator>Leblanc, Roger</creator><creator>de Souza Rebouças, Juliana</creator><creator>Farias, Leonardo Paiva</creator><creator>de Oliveira, Ronaldo Nascimento</creator><creator>Pena, Lindomar</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1553-0533</orcidid></search><sort><creationdate>20210110</creationdate><title>Ivermectin: an award-winning drug with expected antiviral activity against COVID-19</title><author>Formiga, Fabio Rocha ; Leblanc, Roger ; de Souza Rebouças, Juliana ; Farias, Leonardo Paiva ; de Oliveira, Ronaldo Nascimento ; Pena, Lindomar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-3b111023eeb0d7124ca6830cbcefeed044e18ca7f500c100770705c27ab718693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Inhalation</topic><topic>Administration, Oral</topic><topic>Aerosols</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>COVID-19 - drug therapy</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Compounding</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Ivermectin - administration & dosage</topic><topic>Ivermectin - therapeutic use</topic><topic>Nanoparticles - chemistry</topic><topic>Randomized Controlled Trials as Topic</topic><topic>SARS-CoV-2 - drug effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Formiga, Fabio Rocha</creatorcontrib><creatorcontrib>Leblanc, Roger</creatorcontrib><creatorcontrib>de Souza Rebouças, Juliana</creatorcontrib><creatorcontrib>Farias, Leonardo Paiva</creatorcontrib><creatorcontrib>de Oliveira, Ronaldo Nascimento</creatorcontrib><creatorcontrib>Pena, Lindomar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Formiga, Fabio Rocha</au><au>Leblanc, Roger</au><au>de Souza Rebouças, Juliana</au><au>Farias, Leonardo Paiva</au><au>de Oliveira, Ronaldo Nascimento</au><au>Pena, Lindomar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ivermectin: an award-winning drug with expected antiviral activity against COVID-19</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2021-01-10</date><risdate>2021</risdate><volume>329</volume><spage>758</spage><epage>761</epage><pages>758-761</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
[Display omitted]
•Ivermectin is an FDA-approved antiparasitic agent, being currently investigated in COVID-19 patients•Ivermectin for COVID-19 is restrained by formulation challenges, whereas only oral dosage forms are available•The delivery of ivermectin by pulmonary route would provide high drug deposition in the airways and lungs•Expected efficacy by using aerosol micro- and nanocarriers containing ivermectin</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33038449</pmid><doi>10.1016/j.jconrel.2020.10.009</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1553-0533</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2021-01, Vol.329, p.758-761 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7539925 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Inhalation Administration, Oral Aerosols Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use COVID-19 - drug therapy Drug Carriers - chemistry Drug Compounding Drug Therapy, Combination Humans Ivermectin - administration & dosage Ivermectin - therapeutic use Nanoparticles - chemistry Randomized Controlled Trials as Topic SARS-CoV-2 - drug effects Treatment Outcome |
| title | Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A55%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ivermectin:%20an%20award-winning%20drug%20with%20expected%20antiviral%20activity%20against%20COVID-19&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Formiga,%20Fabio%20Rocha&rft.date=2021-01-10&rft.volume=329&rft.spage=758&rft.epage=761&rft.pages=758-761&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2020.10.009&rft_dat=%3Celsevier_pubme%3ES0168365920305800%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33038449&rft_els_id=S0168365920305800&rfr_iscdi=true |